Journal ArticleOPEN ACCESS

Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2–Negative Breast Cancer?

  • Esteva F
The Oncologist (2008) 13(4) 370-372
DOI: 10.1634/theoncologist.2008-0050
3Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This commentary evaluates the study of Ardavanis et al. in this issue and makes recommendations for further studies of HER-2 extracellular domain circulating levels as a prognostic indicator in metastatic breast cancer.

Cite

CITATION STYLE

APA

Esteva, F. J. (2008). Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2–Negative Breast Cancer? The Oncologist, 13(4), 370–372. https://doi.org/10.1634/theoncologist.2008-0050

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free